<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34629462</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1643-3750</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><PubDate><Year>2021</Year><Month>Oct</Month><Day>11</Day></PubDate></JournalIssue><Title>Medical science monitor : international medical journal of experimental and clinical research</Title><ISOAbbreviation>Med Sci Monit</ISOAbbreviation></Journal><ArticleTitle>Editorial: Multisystem Inflammatory Syndrome in Adults (MIS-A) and the Spectrum of COVID-19.</ArticleTitle><Pagination><StartPage>e935005</StartPage><MedlinePgn>e935005</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.12659/MSM.935005</ELocationID><Abstract><AbstractText>Recent studies on the pathogenesis and clinical spectrum of human disease following infection with the new human pathogen, SARS-CoV-2, have identified the varied presentations and sequelae of COVID-19. Acute 'cytokine storm' in severe COVID-19 results in multiorgan damage due to vascular hyperpermeability, edema, and hypercoagulation. The long-term consequences of infection from SARS-CoV-2 include long COVID. or post-COVID syndrome, and multisystem inflammatory syndrome in children (MIS-C). Several case reports of multisystem inflammatory syndrome in adults (MIS-A) have shown the presentation at more than four weeks after initial infection with SARS-CoV-2 in adults more than 21 years of age. In September 2021, a published systematic review of the literature identified 221 patients with MIS-A, representing the most comprehensive clinical study to date. MIS-A occurs in the post-acute COVID-19 period. The pathogenesis may involve a dysregulated antibody-mediated immune response, similar to MIS-C. Therefore, patients with MIS-A may respond to supportive therapies that control hyperinflammation. This Editorial aims to describe MIS-A and discuss COVID-19 as a spectrum of hyperinflammatory disease in terms of severity, extent, duration, and patient age.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Parums</LastName><ForeName>Dinah V</ForeName><Initials>DV</Initials><AffiliationInfo><Affiliation>Science Editor, Medical Science Monitor, International Scientific Information, Inc., Melville, NY, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Med Sci Monit</MedlineTA><NlmUniqueID>9609063</NlmUniqueID><ISSNLinking>1234-1010</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000080424" MajorTopicYN="N">Cytokine Release Syndrome</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018746" MajorTopicYN="N">Systemic Inflammatory Response Syndrome</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of interest:</b> None declared</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>11</Day><Hour>5</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>10</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34629462</ArticleId><ArticleId IdType="pmc">PMC8518511</ArticleId><ArticleId IdType="doi">10.12659/MSM.935005</ArticleId><ArticleId IdType="pii">935005</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Parasher A. COVID-19: Current understanding of its pathophysiology, clinical presentation and treatment. Postgrad Med J. 2021;97(1147):312&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10017004</ArticleId><ArticleId IdType="pubmed">32978337</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature News. COVID research: a year of scientific milestones. Nature. 2021 May 5;2021 doi: 10.1038/d41586-020-00502-w. Epub ahead of print. Available from:  https://www.nature.com/articles/d41586-020-00502-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-020-00502-w</ArticleId><ArticleId IdType="pubmed">32221507</ArticleId></ArticleIdList></Reference><Reference><Citation>Siemieniuk RA, Bartoszko JJ, Ge L, et al. Drug treatments for COVID-19: living systematic review and network meta-analysis. BMJ. 2020;370:m2980.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7390912</ArticleId><ArticleId IdType="pubmed">32732190</ArticleId></ArticleIdList></Reference><Reference><Citation>Malone B, Campbell EA. Molnupiravir: Coding for catastrophe. Nat Struct Mol Biol. 2021;28(9):706&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">34518697</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Zhong X, Wang Y, et al. Clinical determinants of the severity of COVID-19: A systematic review and meta-analysis. PLoS One. 2021;16(5):e0250602.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8092779</ArticleId><ArticleId IdType="pubmed">33939733</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institutes of Health (NIH) COVID-19 treatment guidelines. Clinical spectrum of SARS-CoV-2 infection. 2021.  Available from:  https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/</Citation><ArticleIdList><ArticleId IdType="pubmed">34003615</ArticleId></ArticleIdList></Reference><Reference><Citation>Weatherhead JE, Clark E, Vogel TP, et al. Inflammatory syndromes associated with SARS-CoV-2 infection: dysregulation of the immune response across the age spectrum. J Clin Invest. 2020;130(12):6194&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7685746</ArticleId><ArticleId IdType="pubmed">33108354</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhary S, Sharma K, Silakari O. The interplay between inflammatory pathways and COVID-19: A critical review on pathogenesis and therapeutic options. Microb Pathog. 2021;150:104673.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7709793</ArticleId><ArticleId IdType="pubmed">33278517</ArticleId></ArticleIdList></Reference><Reference><Citation>Webb BJ, Peltan ID, Jensen P, et al. Clinical criteria for COVID-19-associated hyperinflammatory syndrome: A cohort study. Lancet Rheumatol. 2020;2(12):e754&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7524533</ArticleId><ArticleId IdType="pubmed">33015645</ArticleId></ArticleIdList></Reference><Reference><Citation>Parums DV. Editorial: Long COVID, or post-COVID syndrome, and the global impact on health care. Med Sci Monit. 2021;27:e933446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8194290</ArticleId><ArticleId IdType="pubmed">34092779</ArticleId></ArticleIdList></Reference><Reference><Citation>Parums DV. Editorial: COVID-19 and multisystem inflammatory syndrome in children (MIS-C) Med Sci Monit. 2021;27:e933369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8176784</ArticleId><ArticleId IdType="pubmed">34075014</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris SB, Schwartz NG, Patel P, et al. Case series of multisystem inflammatory syndrome in adults associated with SARS-CoV-2 infection &#x2013; United Kingdom and United States, March&#x2013;August 2020. MMWR Morb Mortal Wkly Rep. 2020;69(40):1450&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7561225</ArticleId><ArticleId IdType="pubmed">33031361</ArticleId></ArticleIdList></Reference><Reference><Citation>Davogustto GE, Clark DE, Hardison E, et al. Characteristics associated with multisystem inflammatory syndrome among adults with SARS-CoV-2 infection. JAMA Netw Open. 2021;4(5):e2110323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8134998</ArticleId><ArticleId IdType="pubmed">34009351</ArticleId></ArticleIdList></Reference><Reference><Citation>Dufort EM, Koumans EH, Chow EJ, et al. New York State and Centers for Disease Control and Prevention Multisystem Inflammatory Syndrome in Children Investigation Team. Multisystem inflammatory syndrome in children in New York State. N Engl J Med. 2020;383(4):347&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7346766</ArticleId><ArticleId IdType="pubmed">32598830</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel P, DeCuir J, Abrams J, et al. Clinical characteristics of multisystem inflammatory syndrome in adults: A systematic review. JAMA Netw Open. 2021;4(9):e2126456.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8459192</ArticleId><ArticleId IdType="pubmed">34550381</ArticleId></ArticleIdList></Reference><Reference><Citation>Chow EJ. The multisystem inflammatory syndrome in adults with SARS-CoV-2 infection &#x2013; another piece of an expanding puzzle. JAMA Netw Open. 2021;4(5):e2110344.</Citation><ArticleIdList><ArticleId IdType="pubmed">34009354</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanson KE, Caliendo AM, Arias CA, et al.   Infectious Diseases Society of America guidelines on the diagnosis of COVID-19: Serologic testing. Infectious Diseases Society of America (IDSA);  Available from:  https://www.idsociety.org/practice-guideline/covid-19-guideline-serology/</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7543294</ArticleId><ArticleId IdType="pubmed">32918466</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>